Associations
newsletter
subscribe
advertise
contact
Technology
pulseTV
Buyer's Guide
Comparison Charts
Blogs
Events
Webinars
Magazine
Cardiac Diagnostics
ECG
ECG Management Systems
Holter Monitoring Systems
Stress Test Systems
Cardiac Imaging
Advanced Visualization
Angiography Systems
Cardiovascular Ultrasound
Contrast Media
CT Systems
Hybrid OR
MRI Systems
Nuclear Imaging
Cath Lab
Angiography Systems
Balloon Catheters
Hemostasis Management
Intravascular Imaging Systems
Interventional Radiology
Hybrid OR
Radial Access
Stents
Ventricular Assist Devices (VAD)
EP Lab
Ablation Systems
Cardiac Resynchronization Therapy Devices (CRT)
Implantable Cardioverter Defibrillators (ICD)
Leads, implantable devices
Pacemakers
Information Technology
Advanced Visualization
Cardiac PACS
Telecardiology
Structural Heart
Heart Valve Repair
Hybrid OR
Left Atrial Appendage (LAA) Occluders
Structural Heart Occluders/Closure Devices
Schering-Plough Corp.
Related Articles
Pharmaceuticals
Drug Attacks Cholesterol In Two Ways
Drug Offers Different Way to Fight Cholesterol
Drug Company Files Cholesterol Medication Patent Challenge
Merck, Schering-Plough Resolve Civil Class-Action Lawsuits Related to VYTORIN, ZETIA
ZETIA, VYTORIN Makers Merck, Schering-Plough Merge in $41.1 Billion Deal
Cholesterol-Lowering Drugs Decrease Coronary Artery Disease, But Not Aortic Valve Disease
Schering-Plough Plans Phase III of Antiplatelet Clinical Trials
General Cardiology
ZETIA, VYTORIN Makers Merck, Schering-Plough Merge in $41.1 Billion Deal
Cardiology Products
ZETIA, VYTORIN Makers Merck, Schering-Plough Merge in $41.1 Billion Deal
Cholesterol-Lowering Drugs Decrease Coronary Artery Disease, But Not Aortic Valve Disease
Clinical Trial/Study
Cholesterol-Lowering Drugs Decrease Coronary Artery Disease, But Not Aortic Valve Disease
